Iktos vs Recursion Pharmaceuticals
Two Pharmaceuticals AI tools, side by side. Both are verified against their own live sites. Here is what each does well and who it is for, so you can choose what fits.
Iktos
iktos.ai
AI and robotics for drug discovery
Best forMedicinal chemistry teams running generative compound design and retrosynthesis planning
PricingEnterprise · current pricing
What it doesIktos offers generative AI and retrosynthesis tools for small-molecule drug discovery. Makya is a generative design platform for multi-parameter compound optimization, Spaya plans synthetic routes, and Iktos Robotics automates synthesis and testing to shorten discovery cycles.
Capabilities
Visit Iktos →- Generative multi-parameter molecule design (Makya)
- AI retrosynthesis route planning (Spaya)
- Automated synthesis and testing robotics
- Compound prioritization against project objectives
Recursion Pharmaceuticals
www.recursion.com
Decoding biology to improve lives
Best forOrganizations seeking AI-led target discovery and molecule optimization at industrial scale through partnership
PricingEnterprise · current pricing
What it doesRecursion operates the Recursion OS, an AI-driven drug discovery platform combining large proprietary biological and chemical datasets, automated wet-lab experimentation, and machine learning models to identify novel targets and design optimized molecules. The platform supports oncology and rare-disease programs.
Capabilities
Visit Recursion Pharmaceuticals →- Phenomics and multi-omics data generation at scale
- Automated high-throughput cell experimentation
- Machine learning target identification
- Molecule design and optimization
How to choose
Choose Iktos if you are medicinal chemistry teams running generative compound design and retrosynthesis planning. Choose Recursion Pharmaceuticals if you are organizations seeking ai-led target discovery and molecule optimization at industrial scale through partnership. Both sit in Pharmaceuticals; the right pick depends on your exact workflow and budget.
Not sure which to pick?
Get our short, vendor-neutral AI briefing and we will help you choose well.
Double opt-in · unsubscribe any time